Table 3.
Severe acute respiratory syndrome coronavirus 2 IgG positive inflammatory bowel disease patients divided by presence or absence of COVID-19 symptoms and ongoing therapy
|
SARS-CoV-2 IgG value > 7
| ||||
|
SARS-CoV-2 IgG positive patients (n, %)
|
Therapy (patients, n, %)
|
Disease
|
|
Total n (%)
|
|
|
|
CD (n)
|
UC (n)
|
|
| COVID-19 symptoms yes (12, 63.2) | Biologic drug (6, 50.0) | 5 | 1 | 6 |
| Azathioprine (4, 33.3) | 1 | 3 | 4 | |
| Mesalazine (2, 16.6) | 0 | 2 | 2 | |
| COVID-19 symptoms no (7, 36.8) | Biologic treatment (4, 57.1) | 4 | 0 | 4 |
| Azathioprine (1, 14.3) | 0 | 1 | 1 | |
| Mesalazine (2, 28.6) | 0 | 2 | 2 | |
| 12 | 7 | 19 | ||
CD: Crohn' s disease; COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; UC: Ulcerative colitis.